Organon contraceptive ‘shows advantages over pill’

A new study of Organon’s hormone-releasing contraceptive ring, NuvaRing, has shown that low levels of hormone exposure associated with the use of the ring have resulted in fewer call backs for doctors. The report also showed that its customers were “over eight times more likely to want to continue its use than pill users”.

The results are based on the findings of two studies. The first one studied the side-effects associated with most patch or oral contraceptives and it examined 200 subjects in a randomised clinical trial, who were more likely to report “no change” or “no bad change” than compared to other types of contraceptives.

The second study recorded the number of call-backs NuvaRing users had to make to the doctor, compared to users of other types of contraception. Again, the ring had a reduced number of call backs in comparison to other contraceptives, mainly for queries relating to the ring rather than medical issues.

Dr Rosella Nappi from the University of Pavia, Italy, said: “Its low hormone exposure combined with its once-a-month action clearly translate into meaningful advantages for women, as evidenced by the high proportion of users who are very satisfied with it and want to continue using it.”

“At the same time, it brings benefits to prescribers in terms of less follow on queries. This makes NuvaRing a very logical contraceptive choice,” she added.

Organon says that NuvaRing reduced the hormonal highs and lows associated with daily pills because it releases oestrogen throughout the day. The company produces six other contraceptive products and offers anaesthetic, neuroscience and fertility drugs.

© Adfero Ltd